Deferred Cytoreductive Nephrectomy in Synchronous Metastatic Renal Cell Carcinoma: The NORDIC-SUN-Trial
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
BACKGROUND: For synchronous metastatic renal cell carcinoma (RCC), surgical resection of the primary tumor in the presence of distant metastases has been the standard of therapy for select patients followed by systemic therapy. In the era of TKIs two randomized trials, CARMENA and SURTIME, have questioned the role and timing of surgery in these patients, results point towards no surgery or a deferred approach. RATIONALE: The antitumor activity of immune checkpoint blockage (ICB) is more potent than other therapy in mRCC. The deferred cytoreductive nephrectomy approach ensures systemic therapy for all patients, avoid systemic treatment delay, and spare surgery in patients with progressive tumors. Current data only point towards a survival benefit for cytoreductive nephrectomy in intermediate risk patients, but not in poor risk patients HYPOTHESIS: Deferred cytoreductive nephrectomy after initial nivolumab combined with ipilimumab or a TKI/IO-combination will improve OS in patients with synchronous metastatic RCC and ≤3 IMDC risk features This is an open, randomized, multicenter comparison trial, designed to evaluate the effect of deferred cytoreductive nephrectomy compared with no surgery following initial nivolumab combined with ipilimumab or a TKI-combination, in mRCC patients with IMDC intermediate and poor risk.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 18 lat
- •Potwierdzony biopsją rak nerki z przerzutami (wszystkie typy histologiczne)
- •Przerzuty obecne w momencie rozpoznania z pierwotnym nowotworem w nerce
- •Zmeasurmalne ogniska nowotworu do oceny odpowiedzi na leczenie
- •Kwalifikacja do leczenia immunologicznego lub celowanego zgodnie z wytycznymi europejskimi
- •Dla kobiet: ujemny test ciążowy i stosowanie antykoncepcji jeśli są w wieku rozrodczym
- •Ogólny stan zdrowia oceniany na co najmniej 70 punktów w skali Karnofskiego
- •Przewidywane przeżycie dłuższe niż 4 miesiące oraz prawidłowe wyniki badań krwi i funkcji organów
✗ Disqualifies
- •Poprzednie leczenie systemowe z powodu raka przerzutowego nerki
- •Inne nowotwory w ciągu ostatnich 3 lat (z wyjątkiem bazalioma skóry i raka prostaty bez wykazania PSA)
- •Duża operacja chirurgiczna lub poważne urazy w ostatnich czterech tygodniach
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- September 23, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (11)
Department of Oncology, Aarhus University Hospital
Aarhus, Denmark
Department of Oncology, Herlev Hospital
Herlev, Denmark
Department of Oncology, Odense University Hospital
Odense, Denmark
Clinical Trial Unit, Helsinki University Central Hospital
Helsinki, Finland
Center for Cancer and Blood Diseases, Vestfold Hospital Trust
Tønsberg, Norway
Department of Oncology, Ålesund Universitetsykehus
Ålesund, Norway
Department of Urology, Haukeland University Hospital
Bergen, Norway
Centre for Cancer Treatment, Sørlandet Hospital Trust, Kristiansand
Kristiansand, Norway
Department of Oncology, Stavanger Universitetssykehus
Stavanger, Norway
Cancer Clinic, St. Olavs Hospital, Trondheim University Hospital
Trondheim, Norway
Department of Oncology, Karolinska University Hospital
Stockholm, Sweden
Trial contact
Niels Fristrup, MD PhD
Ane Iversen, MD PhD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/24/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.